Advanced search
Publication Cover
Expert Review of Ophthalmology Volume 8, 2013 - Issue 5
Submit an article Journal homepage
59
Views
5
CrossRef citations to date
0
Altmetric
Perspectives

Is there an anti-adenoviral drug on the horizon?

Eric G RomanowskiMedicin The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, Ophthalmology and Visual Sciences Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, at the Eye & Ear Institute, Room 1020, 203 Lothrop Street, Pittsburgh, PA 15213, USA+1 412 647 2245+1 412 647 [email protected]
Pages 427-435 | Published online: 09 Jan 2014

References

  • Gordon JS, Aoki K, Kinchington PR. Adenovirus keratoconjunctivitis. In: Ocular Infection & Immunity. Pepose JS, Holland GN, Wilhelmus KR ( Eds). Mosby, St Louis, USA, 877–894 (1996).
  • Nakamura M, Hirano E, Kowada K et al. Surveillance of Adenovirus D in patients with epidemic keratoconjunctivitis from Fukui Prefecture, Japan, 1995–2010. J. Med. Virol. 84(1), 81–86 (2012).
  • Gordon YJ, Romanowski EG, Araullo-Cruz T. An ocular model of adenovirus type 5 infection in the NZ rabbit. Invest. Ophthalmol. Vis. Sci. 33(3), 574–580 (1992).
  • Tsai JC, Garlinghouse G, McDonnell PJ, Trousdale MD. An experimental animal model of adenovirus-induced ocular disease. The cotton rat. Arch. Ophthalmol. 110(8), 1167–1170 (1992).
  • Gordon YJ, Romanowski EG, Araullo-Cruz T, De Clercq E. Pre-treatment with topical 0.1% S-HPMPC inhibits adenovirus type 5 replication in the NZ rabbit ocular model. Cornea 11(6), 529–533 (1992).
  • Trousdale MD, Goldschmidt PL, Nobrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 13(5), 435–439 (1994).
  • Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest. Ophthalmol. Vis. Sci. 35(12), 4135–4143 (1994).
  • Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest. Ophthalmol. Vis. Sci. 41(2), 460–463 (2000).
  • Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest. Ophthalmol. Vis. Sci. 42(8), 1812–1815 (2001).
  • Gordon YJ, Romanowski EG, Araullo-Cruz et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-Cyclic GMP on different ocular adenoviral serotypes in vitro. Antiviral Res. 16(1), 11–16 (1991).
  • De Clercq E. Therapeutic potential of HPMPC as an antiviral. Rev. Medic. Virol. 3(2), 85–96 (1993).
  • Gordon, YJ. Adenovirus pathogenesis and therapy. Presented at: Second International Conference on Ocular Infections. Munich, Germany, 22 August–26 August 1998.
  • Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice-daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 52(3), 275–280 (2001).
  • Romanowski EG, Yates KA, Teuchner B et al. N-Chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest. Ophthalmol. Vis. Sci. 47(5), 2021–2026 (2006).
  • Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A. Efficacy of topical immunoglobulins (IG) against experimental adenoviral ocular infection. Invest. Ophthalmol. Vis. Sci. 48(9), 4171–4176 (2007).
  • Romanowski EG, Yates KA, Gordon YJ. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections. Invest. Ophthalmol. Vis. Sci. 50(11), 5295–5299 (2009).
  • Romanowski EG, Bowlin TL, Yates KA, Mah FS, Gordon YJ. Topical NMSO3 inhibits adenovirus replication in the Ad5/NZW rabbit ocular model. Presented at: ARVO 2004. Fort Lauderdale, FL, USA, 25 April–29 April 2004.
  • Romanowski EG, Yates KA, Kowalski RP, Mah FS, Gordon YJ. A novel topical antiviral agent, PCL-016 (picolinic acid), inhibits adenovirus replication in the Ad5/NZW rabbit ocular model. Presented at: ARVO 2005. Fort Lauderdale, FL, USA, 1 May–5 May 2005.
  • Romanowski EG, Yates KA, Gordon YJ. Cyclopentenylcytosine (CPE-C) inhibits adenovirus replication in the Ad5/NZW rabbit ocular model. Presented at: ARVO 2008. Fort Lauderdale, FL, USA, 27 April–1 May 2008.
  • Gordon YJ, Yates KA, Romanowski EG, Stroman DW. Topical N,N-dichloro-2,2-dimethyltaurine (AL-46383A) inhibits adenovirus replication in the ocular Ad5/NZW rabbit replication model. Presented at: ARVO 2010. Fort Lauderdale, FL, USA, 2 May–6 May 2010.
  • Epstein SP, Pashinsky YY, Gershon D et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmology. 6, 22 (2006).
  • Clement C, Capriotti JA, Kumar M et al. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Invest. Ophthalmol. Vis. Sci. 52(1), 339–344 (2011).
  • Epstein SP, Fernandez KB, Carter BM et al. Safety and efficacy of ganciclovir ophthalmic gel for treatment of adenovirus keratoconjunctivitis utilizing cell culture and animal models. Presented at: ARVO 2012. Fort Lauderdale, FL, USA, 6 May–10 May 2012.
  • Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J. Clin. Invest. 70(3), 598–607 (1982).
  • Wang LKB, Najafi R. N-Chloro-2,2-dimethyltaurines: a new class of remarkably stable N-chlorotaurines. Tetrahedron Lett. 49(14), 2193–2195 (2008).
  • D’Lima L, Friedman L, Wang L et al. No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli. Antimicrob. Agents Chemother. 56(5), 2753–2755 (2012).
  • Jekle A, Rani SA, Celeri C et al. Broad-spectrum virucidal activity of (NVC-422) N,N-dichloro-2,2-dimethyltaurine against viral ocular pathogens in vitro. Invest. Ophthalmol. Vis. Sci. 54(2), 1244–1251 (2013).
  • Yoon J, Jekle A, Ruado F et al. Mechanism of inactivation of adenovirus type 5 by NVC-422, a novel N-chlorotaurine analogue. Antiviral Res. 92(3), 470–478 (2011).
  • Romanowski EG, Yates KA, Gordon YJ, Stroman DW. In vitro evaluation of N,N-dichloro-2,2-dimethyltaurine (AL-46383A) as an antiviral agent against adenovirus and HSV-1. Presented at: ARVO 2010. Fort Lauderdale, FL, USA, 2 May–6 May 2010.
  • Sunil KP, Raja BP, Jagadish RG, Uttam A. Povidone iodine-revisited. Indian J. Dental Advancements 3(3), 617–620 (2011).
  • Monnerat N, Bossart W, Thiel MA. Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study. Klin. Monatsbl. Augenheilkd. 223(5), 349–352 (2006).
  • Rutala WA, Peacock JE, Gergen MF, Sobsey MD, Weber DJ. Efficacy of hospital germicides against adenovirus 8, a common cause of epidemic keratoconjunctivitis in health care facilities. Antimicrob. Agents Chemother. 50(4), 1419–1424 (2006).
  • Sauerbrei A, Sehr K, Brandstädt A et al. Sensitivity of human adenoviruses to different groups of chemical biocides. J. Hosp. Infect. 57(1), 59–66 (2004).
  • Hutter H. Epidemic keratoconjunctivitis: treatment results during an epidemic. Klin. Monatsbl. Augenheilkd. 197(9), 214–217 (1990).
  • Isenberg SJ, Apt L, Valenton M et al. A Controlled Trial of Povidone–Iodine to Treat Infectious Conjunctivitis in Children. Am. J. Ophthalmol. 134(5), 681–688 (2002).
  • Trinavarat A, Atchaneeyasakul L. Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: A pilot study. J. Ocul. Pharmacol. Ther. 28(1), 53–58 (2012).
  • Pelletier JS, Stewart K, Trattler W et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv. Ther. 26(8), 776–783 (2009).
  • Sambursky R. Tauber S. Schirra F. Kozich K. Davidson R. Cohen EJ. The RPS adeno detector for diagnosing adenoviral conjunctivitis. Ophthalmology 113(10), 1758–1764 (2006).
  • McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 61(8), 1153–1183 (2001).
  • Croxtall JD. Ganciclovir ophthalmic gel 0.15% in acute herpetic keratitis (dendritic ulcers). Drugs 71(5), 603–610 (2011).
  • Naesens L, Lenaerts L, Andrei G et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 49(3), 1010–1016 (2005).
  • Tabbara KF, Jarade EF. Ganciclovir effects in adenoviral keratoconjunctivitis. Presented at: ARVO 2001. Fort Lauderdale, FL, USA, 29 April–4 May 2001.
  • Yabiku ST, Yabiku MM, Bottós KM, Araújo AL, de Freitas D, Belfort RJr. Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis. Arq. Bras. Oftalmol. 74(6), 417–421 (2011).
  • Nagl M, Teuchner B, Pottinger E, Ulmer H, Gottardi W. Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis: a phase II pilot study. Ophthalmologica 214(2), 111–114 (2000).
  • Romanowski EG, Roba LA, Wiley LA, Araullo-Cruz T, Gordon YJ. The effects of corticosteroids on adenoviral replication. Arch. Ophthalmol. 114(5), 581–585 (1996).
  • Romanowski EG, Yates KA, Gordon YJ. Short-term treatment with a potent topical corticosteroid of an acute ocular adenoviral infection in the New Zealand white rabbit. Cornea 20(6), 657–660 (2001).
  • Romanowski EG, Yates KA, Gordon YJ. Topical corticosteroids of limited potency promote adenovirus replication in the Ad5/NZW rabbit ocular model. Cornea 21(3), 289–291 (2002).
  • Romanowski EG, Araullo-Cruz T, Gordon YJ. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Invest. Ophthalmol. Vis. Sci. 38(1), 253–257 (1997).
  • Harvey R, Brown K, Zhang Q et al. GSK983: A novel compound with broad-spectrum antiviral activity. Antiviral Res. 82(1), 1–11 (2009).
  • Uchio E, Inoue H, Fuchigami A, Kadonosono K. Anti-adenoviral effect of interferon-b and interferon-g in serotypes that cause acute keratoconjunctivitis. Clin. Exp. Ophthalmol. 39, 358–363 (2011).
  • Eckstein A, Größl T, Geisler A et al. Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. Antiviral Res. 88(1), 86–94 (2010).
  • Kneidinger D, Ibrišimovic M, Lion T, Klein R. Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Res. 94(3), 195–207 (2012).
  • Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 23(1–2), 75–111 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.